ReviewImmunology2014
Clinical implications of interferon-γ genetic and epigenetic variants.
Review in Immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Guideline
- Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.American journal of clinical dermatology · 2021Trial
- Human immunity to fungal infections.The Journal of experimental medicine · 2025Review
- Inactivated vaccines derived from bovine viral diarrhea virus B3 strain elicit robust and specific humoral and cellular immune responses.Frontiers in microbiology · 2025Article
- Cell-Mediated Immune Responses toFrontiers in immunology · 2020Article
- Congenital Transmission ofFrontiers in microbiology · 2019Review
- Immunological monitoring for prediction of clinical response to antitumor vaccine therapy.Oncotarget · 2018Article
- A single nucleotide polymorphism of the interferon-γ gene and susceptibility to hepatitis B virus-related cirrhosis: a randomized controlled trial.International journal of clinical and experimental pathology · 2018Article
- The Serum Level of IL-1B Correlates with the Activity of Chronic Pulmonary Aspergillosis.Canadian respiratory journal · 2018Article
- Hypermethylation of IFN-γ in oral cancer tissues.Clinical oral investigations · 2017Article
- Dysregulation of Innate Lymphoid Cells in Common Variable Immunodeficiency.Current allergy and asthma reports · 2017Review
- Innate and Adaptive Immune Defects in Chronic Pulmonary Aspergillosis.Journal of fungi (Basel, Switzerland) · 2017Article
- The relationship of serum vitamins A, D, E and LL-37 levels with allergic status, tonsillar virus detection and immune response.PloS one · 2017Article
- Chronic Pulmonary Aspergillosis-Where Are We? and Where Are We Going?Journal of fungi (Basel, Switzerland) · 2016Review
- Mycobacterial Metabolic Syndrome: LprG and Rv1410 Regulate Triacylglyceride Levels, Growth Rate and Virulence in Mycobacterium tuberculosis.PLoS pathogens · 2016Article
- Chronic Aspergillosis of the Lungs: Unravelling the Terminology and Radiology.European radiology · 2015Review
- Type I IFN family members: similarity, differences and interaction.Cytokine & growth factor reviews · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interferon-γ (IFN-γ) is an integral and critical molecule of the immune system, with multiple functions, mostly related to the T helper type 1 (Th1) response to infection. It is critical for defence against mycobacterial infection and is of increasing interest in defence against fungi. In this article, we review the genetic and epigenetic variants affecting IFN-γ expression and investigate its role in disease, with an emphasis on fungal diseases such as invasive and chronic pulmonary aspergillosis. Over 347 IFN-γ gene variants have been described, in multiple ethnic populations. Many appear to confer a susceptibility to disease, especially tuberculosis (TB) and hepatitis, but also some non-infectious conditions such as aplastic anaemia, cervical cancer and psoriasis. Several epigenetic modifications are also described, increasing IFN-γ expression in Th1 lymphocytes and reducing IFN-γ expression in Th2 lymphocytes. Recombinant IFN-γ administration is licensed for the prophylaxis of infection (bacterial and fungal) in patients with the phagocyte functional deficiency syndrome chronic granulomatous disease, although the benefits appear limited. Interferon-γ therapy is given to patients with profound defects in IFN-γ and interleukin-12 production and appears to be beneficial for patients with invasive aspergillosis and cryptococcal meningitis, but the studies are not definitive. A high proportion of patients with chronic pulmonary aspergillosis are poor producers of IFN-γ in response to multiple stimuli and could also benefit from IFN-γ administration. The investigation and management of patients with possible or demonstrated IFN-γ deficiency in adulthood is poorly studied and could be greatly enhanced with the integration of genetic data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.